Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

November 12, 2020November 12, 2020

ACR Updates JIA Treatment Guidelines to Emphasize Disease-modifying Therapies

News

The American College of Rheumatology (ACR) has issued new guidelines for treating juvenile idiopathic arthritis (JIA) that emphasize the use of disease-modifying therapies that have recently become available. The 2021 ... Read more

October 29, 2020October 29, 2020

Timing of Arthritis Flares Linked to Eye Inflammation in JIA, Study Finds

News

Eye inflammation tends to occur around the same time as arthritis flares in children with juvenile idiopathic arthritis (JIA), a new study indicates. This finding suggests that JIA patients’ eyes ... Read more

October 2, 2020October 2, 2020

FDA Approves Janssen’s Simponi Aria for Juvenile Arthritis Indications

News

The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Simponi Aria (golimumab) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) in individuals ages 2 ... Read more

October 1, 2020October 1, 2020

FDA Approves Xeljanz for Polyarticular JIA

News

Xeljanz (tofacitinib) has become the first medication in its class to be approved by the U.S. Food and Drug Administration (FDA) as a treatment for polyarticular juvenile idiopathic arthritis (pJIA). ... Read more

July 10, 2020July 10, 2020

Hulio, Biosimilar of Humira, Wins FDA Approval for JIA, But Not Available Until 2023

News

The U.S. Food and Drug Administration (FDA) has approved Hulio, a biosimilar of Humira (adalimumab), for the treatment of juvenile idiopathic arthritis (JIA) in individuals ages 4 and older. However, the biosimilar will ... Read more

June 19, 2020June 19, 2020

MEFV Gene Mutation May Be Risk Factor for sJIA, Study Suggests

News

A specific mutation in the MEFV gene, which has been linked to inflammation, may be a risk factor for developing systemic juvenile idiopathic arthritis (sJIA), a study in China suggests. ... Read more

May 22, 2020May 22, 2020

Short Film on Woman with Juvenile Arthritis Highlights Awareness Month

News

A new short film called “Joint Effort” traces the journey of Zoe Zeerip, a Michigan woman who was diagnosed with juvenile idiopathic arthritis (JIA) at age 13. “At such a ... Read more

May 15, 2020May 15, 2020

Janssen Seeks FDA Approval for Simponi Aria in JIA Subtypes

News

Janssen has submitted two new applications to the U.S. Food and Drug Administration (FDA) seeking approval for Simponi Aria (golimumab), in combination with methotrexate, for the treatment of polyarticular juvenile idiopathic ... Read more

April 2, 2020April 2, 2020

CHMP Recommends Enbrel Biosimilar Nepexto for Approval in Europe

News

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Nepexto, a biosimilar of Enbrel (etanercept), for the treatment of various inflammatory disorders including juvenile idiopathic arthritis. ... Read more

February 7, 2020February 7, 2020

Asian Mothers with JIA Aren’t at Greater Risk of Pregnancy Complications, Study Finds

News

Asian mothers with juvenile idiopathic arthritis (JIA) are not at greater risk of pregnancy- or birth-related complications than mothers without the disorder, a study found. The study, “Pregnancy outcomes and ... Read more